Cargando…

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

BACKGROUND: Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with no need f...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Hise, Nicholas, Petrak, Russell M., Skorodin, Nathan C., Fliegelman, Robert M., Anderson, Michael, Didwania, Vishal, Han, Alice, Shah, Kairav, Chundi, Vishnu, Hines, David, Roig, Ingrid, Kalra, Apoorv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680490/
https://www.ncbi.nlm.nih.gov/pubmed/33063176
http://dx.doi.org/10.1007/s40121-020-00351-0
_version_ 1783612444940173312
author Van Hise, Nicholas
Petrak, Russell M.
Skorodin, Nathan C.
Fliegelman, Robert M.
Anderson, Michael
Didwania, Vishal
Han, Alice
Shah, Kairav
Chundi, Vishnu
Hines, David
Roig, Ingrid
Kalra, Apoorv
author_facet Van Hise, Nicholas
Petrak, Russell M.
Skorodin, Nathan C.
Fliegelman, Robert M.
Anderson, Michael
Didwania, Vishal
Han, Alice
Shah, Kairav
Chundi, Vishnu
Hines, David
Roig, Ingrid
Kalra, Apoorv
author_sort Van Hise, Nicholas
collection PubMed
description BACKGROUND: Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with no need for adjustment in renal dysfunction. In the concomitant administration with CYP 3A4-inducing drugs, eravacycline dosing should be modified. OBJECTIVE: To evaluate the efficacy and safety of eravacycline in a range of infections such as intraabdominal infections, pneumonia and diabetic foot infections in seriously ill patients. METHODS: A retrospective observational cohort study using electronic patient records of 50 consecutive patients administered eravacycline during inpatient acute care admission or as part of outpatient antibiotic therapy (OPAT). RESULTS: Therapy of 1.5 mg/kg q24h was initiated in the hospital in most patients, although some of the less sick were managed in the office or OPAT setting. All patients concluded their management outside of the hospital. Of the 50 patients, 47 (94%) achieved clinical resolution of their infection and 3 (6%) clinical failures occurred. Only three (6%) patients did not have comorbidities, three had a single comorbidity (6%), and the majority (88%) of patients had two or more comorbidities. Most common infections were intraabdominal (36%), pneumonia (18%), diabetic foot (12%), spontaneous bacterial peritonitis (8%) and empyema (8%). Almost half of infections had more than one pathogen isolated, and resistant isolates were frequent. The drug was well tolerated with only two reports of nausea, which did not result in treatment discontinuation, and in 30 days of post-eravacycline therapy only one case of Clostridiodes difficile. CONCLUSIONS: In this real-world setting, eravacycline demonstrated a similar high level of clinical efficacy as seen in clinical trials, 94%, in a variety of infections, including against multidrug-resistant bacteria, and was well tolerated.
format Online
Article
Text
id pubmed-7680490
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-76804902020-11-23 A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline Van Hise, Nicholas Petrak, Russell M. Skorodin, Nathan C. Fliegelman, Robert M. Anderson, Michael Didwania, Vishal Han, Alice Shah, Kairav Chundi, Vishnu Hines, David Roig, Ingrid Kalra, Apoorv Infect Dis Ther Original Research BACKGROUND: Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with no need for adjustment in renal dysfunction. In the concomitant administration with CYP 3A4-inducing drugs, eravacycline dosing should be modified. OBJECTIVE: To evaluate the efficacy and safety of eravacycline in a range of infections such as intraabdominal infections, pneumonia and diabetic foot infections in seriously ill patients. METHODS: A retrospective observational cohort study using electronic patient records of 50 consecutive patients administered eravacycline during inpatient acute care admission or as part of outpatient antibiotic therapy (OPAT). RESULTS: Therapy of 1.5 mg/kg q24h was initiated in the hospital in most patients, although some of the less sick were managed in the office or OPAT setting. All patients concluded their management outside of the hospital. Of the 50 patients, 47 (94%) achieved clinical resolution of their infection and 3 (6%) clinical failures occurred. Only three (6%) patients did not have comorbidities, three had a single comorbidity (6%), and the majority (88%) of patients had two or more comorbidities. Most common infections were intraabdominal (36%), pneumonia (18%), diabetic foot (12%), spontaneous bacterial peritonitis (8%) and empyema (8%). Almost half of infections had more than one pathogen isolated, and resistant isolates were frequent. The drug was well tolerated with only two reports of nausea, which did not result in treatment discontinuation, and in 30 days of post-eravacycline therapy only one case of Clostridiodes difficile. CONCLUSIONS: In this real-world setting, eravacycline demonstrated a similar high level of clinical efficacy as seen in clinical trials, 94%, in a variety of infections, including against multidrug-resistant bacteria, and was well tolerated. Springer Healthcare 2020-10-15 2020-12 /pmc/articles/PMC7680490/ /pubmed/33063176 http://dx.doi.org/10.1007/s40121-020-00351-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Van Hise, Nicholas
Petrak, Russell M.
Skorodin, Nathan C.
Fliegelman, Robert M.
Anderson, Michael
Didwania, Vishal
Han, Alice
Shah, Kairav
Chundi, Vishnu
Hines, David
Roig, Ingrid
Kalra, Apoorv
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title_full A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title_fullStr A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title_full_unstemmed A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title_short A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
title_sort real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680490/
https://www.ncbi.nlm.nih.gov/pubmed/33063176
http://dx.doi.org/10.1007/s40121-020-00351-0
work_keys_str_mv AT vanhisenicholas arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT petrakrussellm arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT skorodinnathanc arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT fliegelmanrobertm arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT andersonmichael arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT didwaniavishal arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT hanalice arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT shahkairav arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT chundivishnu arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT hinesdavid arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT roigingrid arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT kalraapoorv arealworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT vanhisenicholas realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT petrakrussellm realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT skorodinnathanc realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT fliegelmanrobertm realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT andersonmichael realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT didwaniavishal realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT hanalice realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT shahkairav realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT chundivishnu realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT hinesdavid realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT roigingrid realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline
AT kalraapoorv realworldassessmentofclinicaloutcomesandsafetyoferavacyclineanovelfluorocycline